129.46
+0.18(+0.14%)
Currency In USD
Address
45 Sidney Street
Cambridge, MA 02139
United States of America
Phone
617 374 7580
Sector
Healthcare
Industry
Biotechnology
Employees
682
First IPO Date
April 30, 2015
| Name | Title | Pay | Year Born |
| Kathryn Haviland | President, Chief Executive Officer & Director | 1.69M | 1976 |
| Alexis A. Borisy | Co-Founder & Director | 50,000 | 1972 |
| Tracey L. McCain | Executive Vice President, Chief Legal & Compliance Officer and Secretary | 764,901 | 1967 |
| Michael Landsittel | Chief Financial Officer | 974,568 | 1972 |
| Percy H. Carter | Chief Scientific Officer | 1.1M | 1971 |
| Christina Rossi | Chief Operating Officer | 1.22M | 1976 |
| Fouad Namouni | President of Research & Development | 1.23M | 1969 |
| Becker Hewes | Chief Medical Officer | 0 | 1966 |
| Georg Meyer | Senior Vice President & Head of International | 0 | N/A |
| Julian Charles Baker | Senior Vice President of Corporate Affairs | 0 | 1967 |
| Sherwin Sattarzadeh | Chief Business Officer | 0 | N/A |
| Ariel Hurley | Senior Vice President of Finance and Principal Accounting Officer | 0 | 1974 |
| Debra Durso-Bumpus | Chief People Officer | 0 | 1970 |
| Jenna Cohen | Senior Director & Head of Investor Relations | 0 | N/A |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.